Full Study Name: A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
Description: This study is designed to test the efficacy and safety of intravenous Ravulizumab in patients with ALS by blocking complement activity. This investigational product has been used in other rare diseases. You have a 2/3 chance of receiving study drug versus placebo. The randomized period of the trial will last 50 weeks. Patients who complete the randomized period of the study may choose to go into the open label extension that will last up to two years.
Principal Investigators: Shafeeq Ladha, MD